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adult patients, and its timing is of paramount importance. 
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 Introduction 
 Ulcerative colitis (UC) exhibits bimodality in age-spe-
cific incidence rates with the second peak occurring at 
60–70 years of age  [1–5] . Almost as many as 10% of pa-
tients with UC have late onset  [6] . The course of the dis-
ease and the basic principles of management in geriatric 
populations do not differ from those in younger patients. 
However, elderly patients pose distinct problems in ther-
apy choice. Since patients older than 60 years are exclud-
ed from most therapeutic trials on severe UC, the treating 
physician is left with many open questions for the elderly 
patient with UC. Unfortunately, even the current ECCO 
guidelines on UC do not live up to expectations  [7–9] . 
Guidelines appear most necessary where evidence is lim-
ited, and therefore such guidelines should cover more 
special situations such as treatment of the elderly patient. 
The aim of this article is to summarize the literature on 
medical treatment of severe UC focusing on (1) the age of 
the patients included in the respective studies, and (2) 
finding age-specific characteristics in current medical 
trials.
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 Abstract 
 Almost as many as 10% of patients with ulcerative colitis 
have late onset with the first flare occurring at 60–70 years 
of age. The course of the disease and the basic principles of 
management in geriatric populations do not differ from 
those in younger patients. However, elderly patients pose 
distinct problems in therapy choice. In middle-aged patients 
untreated severe ulcerative colitis has been reduced to  ! 1% 
in specialized centers at the present time but is still high in 
the elderly. In general, the management requires close col-
laboration between gastroenterologists and surgeons. In 
adult patients, current evidence supports initial treatment 
with intravenous steroids. However, only 40% of patients 
show complete response after corticosteroid therapy and al-
most 30% come to colectomy. Cyclosporine still has a first 
place as salvage therapy because of its short half-life and its 
established short-term efficacy in about 70% of patients 
who fail steroids. The drug should be avoided in frail or el-
derly patients (especially over 80 years old) with significant 
comorbidity, and also where colectomy is likely to be neces-
sary in the short to medium term. The long-term benefit of 
this therapy remains unsatisfactory as colectomy is often 
only delayed. Infliximab is the choice for those patients with 
a less severe colitis and less likelihood of urgent colectomy. 
Tacrolimus has only been used in one randomized controlled 
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Table 1. Therapy options in patients with moderate and severe UC
Author Drug Regime Study
type
Year Patients Response/remission Age
(range)
Study
period
Intensive intravenous steroid treatment (IIVST)  
Truelove [10] IIVST cortisone
100 mg/day i.v.
Controlled
trial, pc
1955 210
(109 cortisone,
101 P)
remission
45/109 = 41% (vs. 16% in P)
response
30/109 = 27% (vs. 24% in P)
no change/worse
34/109 = 31% (vs. 60% P)
NA 6 weeks
Truelove [11] IIVST prednisolone 60 mg/day
i.v. hydrocortisone
100 mg rectally/day
Case series 1974 49 remission 36/49 = 73%
response 4/49 = 8%
no change/worse 9/49 = 18%
NA 5 days
Truelove [12] IIVST prednisolone 60 mg/day
i.v. hydrocortisone
100 mg rectally/day
Case series 1978 100 remission 60/100 = 60%
response 15/100 = 15%
no change/worse 25/100 = 25%
5–84 5 days
Meyers [23] IIVST hydrocortisone 
300 mg/day vs. cortico-
tropin 120 U/day i.v.
RCT, db 1983 66 remission 28/66 = 42% 10 days
Cyclosporine A (CyA)
Lichtiger [14] CyA 4 mg/kg vs.
placebo
RCT, db 1994 20
(11 CyA, 9 P)
response CyA: 9/11 = 82%
P: 0/9 = 0%
34
(18–60)
7 days
D’Haens [15] CyA 4 mg/kg vs. 40 mg
M-pred
RCT, db 2001 30
(14 CyA, 15
M-pred, 1 DA)
response: CyA: 9/14 = 64%
M-pred: 8/15 = 53%
36
(20–67)
8 days 
Infliximab (IFX)
Järnerot [17] IFX 1 ! 5 mg/kg RCT, db 2005 45
(24 IFX, 21 P)
colectomy rate IFX: 7/24 = 29%
P: 14/21 = 67%
37
(19–61)
3 
months
Ochsenkühn 
[38]
IFX 5 mg/kg week 0/2/6 vs.
prednisolone 1.5 mg/kg
RCT, db 2004 13
(6 IFX, 7 pred-
nisolone)
response: IFX: 5/6 = 83%
prednisolone: 6/7 = 85%
31
(21–44)
13 weeks
Probert [39] IFX 5 mg/kg week 0/2 RCT, pc 2003 43
(23 IFX, 20 P)
remission: IFX 9/23 = 39%
P 6/20 = 30%
41
(29–50)
8 weeks
Rutgeerts [36] IFX 5 mg/kg, 10 mg/kg,
placebo at week 0/2/6
then every 8 weeks
RCT, db 2005 364 (ACT1)
364 (ACT2):
121 P, 121 IFX
5 mg/kg, 121 IFX
10 mg/kg
ACT1 week 8 response:
IFX 69% 5 mg/kg vs. 37% placebo
ACT2 week 8: IFX 64% 5 mg/kg
vs. 29% placebo
42 ACT 1:
46 weeks
ACT 2:
22 weeks
Sands [40] IFX 5 mg/kg, 10 mg/kg,
20 mg/kg, placebo
RCT, db 2001 11
8 IFX, 3 P
response: IFX 4/8 = 50%
P: 0/3 = 0%
37
31–63
2 weeks
Armuzzi [37] IFX 5 mg/kg at week 0/2/6
then every 8 weeks;
M-pred 0.7–1 mg/kg/day
RCT, 
open-label
2004 20
10 IFX, 10 M-pred
remission 24–53 2 weeks
Tacrolimus (Tacro)
Ogata [18] Tacro 0.05 mg/kg/day RCT, db 2006 65
21 high conc.
(10–15 ng/ml)
22 low conc.
(5–10 ng/ml), 20 P
response:
high conc.: 13/19 = 68%
low conc.: 8/21 = 38%
P: 2/20 = 10%
33 2 weeks
IIVST = Intensified intravenous steroid therapy; CyA = cyclosporine A; IFX = infliximab; Tacro = tacrolimus; RCT = randomized controlled trial; 
db = double-blind; pc = placebo-controlled; DA = drop-out; P = placebo; M-pred = methylprednisone.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
1/
20
16
 4
:2
3:
02
 P
M
 Treatment of Severe Ulcerative Colitis  Dig Dis 2009;27:315–321 317
 Medical Treatment of Uncomplicated Severe 
Ulcerative Colitis 
 Patients with severely active UC can be treated ini-
tially with oral corticosteroids. Those patients failing 
may require hospitalization for administration of intra-
venous corticosteroids  [10–12] . In patients who present 
as steroid-refractory UC or treatment failure, CMV coli-
tis has to be excluded by sigmoidoscopy with biopsies. It 
is believed that CMV colitis might be responsible for 
treatment failures in UC patients in up to 10%  [13] . Cy-
closporine, infliximab, and tacrolimus are used as res-
cue therapy in patients with severe UC who fail intrave-
nous corticosteroids  [14–18] . All three therapies are 
graded as evidence level EL1b in intravenous-steroid re-
sistant UC of any extent in the new ECCO guidelines  [8] . 
The different medical treatment modalities (steroids, 
cyclosporine, infliximab, and tacrolimus) will be dis-
cussed in the following section and a summary of those 
studies can be found in  table 1 . A special focus was 
posed on the age range of patients who have been in-
cluded in the respective studies.  Table 2 summarizes the 
most relevant statements regarding elderly patients with 
severe UC.
 Steroids 
 Steroids are efficacious in UC and severe attacks of UC 
are treated with intensified intravenous steroid therapy 
(IIVST). The first placebo-controlled trial on steroid 
therapy in severe UC was reported by Truelove and Witts 
 [10]  in 1955. In this trial, remission was achieved in 41%, 
response in 27% and no change/worse outcome was not-
ed in 31% of patients, respectively ( table 1 ). Despite this 
established treatment, severe flares of UC have a high col-
ectomy rate varying from 38 to 47%  [11, 19] . Of patients 
with UC affecting the entire colon, up to 60% have been 
reported to have surgery within three months  [19] . How-
ever, this may vary from country to country. Colectomy 
rates especially in northern Europe are higher as com-
pared to central and southern Europe. Clearly colectomy 
rates in Switzerland are lower in newly diagnosed panco-
litis.
 In 1974, Truelove and Jewell  [11] described the Oxford 
regimen for the treatment of severe UC ( table 1 ). This re-
gime is essentially based on the use of intravenous corto-
costeroids (hydrocortisone 100 mg 4 ! /day or methyl-
prednisone 60–80 mg/day with hydrocortisone 100 mg 
rectally/day), the meticulous monitoring of patients and 
clear decision making concerning surgery  [11, 12] . It was 
reported that 60% of patients had a complete response 
and 15% showed improvement to this therapy  [12] . The 
lack of improvement to this intensive therapy by day 5 is 
considered an absolute indication for emergency colec-
tomy  [11–12, 20] . In a systematic review of 32 trials of 
steroid therapy for acute severe UC involving 1,991 pa-
tients from 1974 to 2006, the overall response to steroids 
(intravenous hydrocortisone, methylprednisolone, or be-
tamethasone) was 67%  [21] . The ECCO consensus on UC 
grades intravenous steroid therapy as evidence level EL1b 
 [8] .
 Studies conducted to compare different types of ste-
roids and adrenocorticotropic hormone did not demon-
strate any clear advantage of one type versus the others 
 [22–24] . Regarding elderly patients, there is only one 
case-control Spanish study, which included patients old-
er than 60 years (8 patients with CD and 25 patients with 
UC). The authors found a higher rate of corticosteroid-
dependent patients leading to an increased requirement 
of immunosuppressive treatment in the elderly group 
 [25] . The Italian Colon-Rectum Study group reported on 
1,705 patients with UC. In this cohort 436 patients were 
under 25 years old and 386 patients were over 50 years 
old. Interestingly, younger patients tended to have a great-
er anatomical-clinical severity with greater use of ste-
roids in the acute phase of UC  [26] .
 Cyclosporine A 
 Promising results from uncontrolled trials  [27, 28] 
were substantiated by a two-center, randomized, place-
bo-controlled trial from North America in which intra-
venous cyclosporine at a dose of 4 mg/kg was given to UC 
patients not responding to intravenous steroids. An ini-
Table 2. Statements regarding elderly patients with UC 
UC patients present with an age-specific incidence rate with a sec-
ond peak occurring at 60–70 years [1]
In elderly patients with UC, there is a higher rate of corticoste-
roid-dependent patients leading to an increased requirement of 
immunosuppressive treatment [25]
UC patients older than 50 years need renal function tests before 
starting cyclosporine therapy [30]
Elderly UC patients either tend to have proctitis or limited left-
sided colitis [1, 26] or present with a severe initial episode with 
toxic megacolon [6]
Early surgical interventions are recommended for elderly patients 
with severe UC [1, 2]
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tial response rate of 82% was described within a mean 
time to response of 7 days, versus 0% in the group that 
received steroids alone ( table 1 )  [14] . In the past decade, a 
few controlled trials and many case series confirmed that 
intravenous cyclosporine at a dose of 2–4 mg/kg/day in-
duces clinical remission in over 50% of the patients in the 
short term so that colectomy can often be avoided  [14–16, 
29] . Cyclosporine has been shown to be at least as effec-
tive as corticosteroids in a double-blind controlled trial 
comparing i.v. cyclosporine with i.v. corticosteroids as 
monotherapy for a severe attack of UC  [15] . The same 
group also reported a randomized, double-blind study 
comparing 4 versus 2 mg/kg intravenous cyclosporine. 
The study showed that the higher-dose cyclosporine has 
no additional clinical benefit over lower-dose cyclospo-
rine in the treatment of severe attacks of UC. Although 
differences in adverse events were not observed, it was 
concluded that because most cyclosporine-associated ad-
verse events are dose dependent, the use of 2 mg/kg 
should improve the long-term toxicity profile of the agent 
 [16] . Although the value of cyclosporine for the manage-
ment of severe UC has been accepted in most referral cen-
ters, concerns about toxicity have prevented its use in 
many hospitals. Cyclosporine can lead to side effects such 
as hypertension, renal failure, hypertrichosis and neuro-
toxicity, which lead to death in some patients, thus limit-
ing its use. However, with the continuous i.v. treatment 
over 24 h such deleterious events have never been report-
ed. Especially patients older than 50 years are more like-
ly to have impaired renal function and must therefore 
have an accurate quantification of creatinine clearance 
before cyclosporine therapy is started  [30] . The benefit of 
avoiding colectomy therefore needs to be balanced against 
the risk of inducing profound immunosuppression and 
severe side effects.
 Long-term prognosis with cyclosporine therapy is re-
ported to be improved by the introduction of azathio-
prine or mercaptopurine on discharge from the hospital 
in association with oral cyclosporine as bridging therapy 
 [31] . Cyclosporine is typically discontinuated after 3–4 
months, the time window which azathioprine needs to 
start its delayed action  [32] . It is even debatable if cyclo-
sporine treatment should be given to a patient who has 
proven azathioprine resistance or intolerance. A recent 
systematic Cochrane review on severe UC has shown that 
the evidence indicating that cyclosporine is more effec-
tive than standard corticosteroid therapy is weak, and 
that cyclosporine does not avoid the overall need for col-
ectomy  [33] . This Cochrane analysis states that ‘the long-
term benefit is unclear, when adverse events such as cy-
closporine-induced nephrotoxicity may become more 
obvious’. Most institutions have therefore restricted the 
use of cyclosporine to patients whose disease is refractory 
to corticosteroids, given the important risk of toxicity 
and the high cost of cyclosporine. Although there is a risk 
of relevant drug toxicity, most patients will opt for cyclo-
sporine if offered, rather than undergo colectomy. A 
study from Cohen et al.  [34] assessed 42 patients who re-
ceived cyclosporine during an acute severe relapse. They 
found that patients who retained their colon felt physi-
cally and psychologically healthier with a significantly 
better quality of life compared with those who had un-
dergone colectomy. On the basis of these observations, 
the systematic use of cyclosporine in severe UC is still 
debated. Moreover, retrospective series showed that, de-
spite an initial response to cyclosporine, many patients 
would eventually undergo proctocolectomy a few years 
down the line  [35] .
 Infliximab 
 More than 15 years ago, the potent anti-inflammatory 
effects of anti-tumor necrosis factor (TNF) therapy with 
the chimeric antibody infliximab were shown in Crohn’s 
disease, in rheumatoid arthritis and later also in UC. Six 
randomized controlled trials were performed to the pres-
ent date for evaluation of induction of remission in pa-
tients with UC  [17, 36–40] . Four studies compared in-
fliximab to placebo  [17, 36, 39, 40] , one study compared 
infliximab to oral steroids  [38] and the other to intrave-
nous corticosteroids  [37] . A small placebo-controlled tri-
al reported in 2001  [40] recruited 11 patients failing 5 
days of i.v. steroids to receive a single dose of infliximab 
or placebo. Four of the eight patients receiving inflix-
imab were deemed treatment success at 2 weeks versus 
none of the three patients given placebo. The trial was 
not continued because of recruitment difficulty. A Scan-
dinavian multicenter randomized placebo-controlled 
trial has recently shown that infliximab given as a single 
5 mg/kg infusion was significantly more effective than 
placebo. In this study, 29% (7/24) of the patients in the 
infliximab group had a colectomy within 90 days (pri-
mary end point), compared with 67% (14/21) in the pla-
cebo group, and this is a statistically significant differ-
ence (p = 0.017)  [17] . The study, however, refers to a fol-
low-up of 3 months and provides no information on the 
long-term follow-up. Two large studies, called ACT1 and 
ACT2, evaluated each 364 patients with active UC. Pa-
tients were randomized to intravenous infusions of in-
fliximab at 5 mg/kg, 10 mg/kg or placebo. Response rates 
were reported to 69% (ACT1) and 64% (ACT2) at week 8 
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 [36] . It should however be noted that hospitalized pa-
tients with severe colitis represent a very different popu-
lation to the outpatients in the ACT1 and ACT2 studies 
and large controlled trials are needed as described in the 
ECCO guidelines  [7–9] .
 In summary, the use of infliximab as a treatment for 
severe UC seems promising, but is not yet clearly defined. 
In particular, whether early use of infliximab will prevent 
colectomy is uncertain.
 Tacrolimus 
 Only one double-blind randomized placebo-con-
trolled study has been performed so far  [8] . This trial 
showed after 2 weeks of treatment clinical remission in 
19% (4/21) of patients in the high target serum concen-
tration group, and in 5% (1/20) in the placebo group. 
Further, a statistically significant dose-dependent rate of 
clinical improvement at 2 weeks and a colectomy-free 
survival of all patients at week 10 were demonstrated. 
Tacrolimus may be effective for short-term clinical im-
provement in patients with refractory UC. It carries 
many of the risks including nephrotoxicity of cyclospo-
rine.
 Special Age-Related Situations in Severe Ulcerative 
Colitis 
 Toxic Megacolon 
 It has been suggested that UC tends to be less extensive 
when it develops later in life; the majority of elderly pa-
tients have proctitis or limited left-sided involvement  [1, 
26] . On the other hand, it has been claimed that older pa-
tients appear to be more likely to present with a severe 
initial episode and to develop toxic megacolon, both of 
which are associated with a high fatality rate. In a com-
munity-based study from Aberdeen, Scotland, 14% of pa-
tients aged over 70 had severe initial episodes, compared 
with 7% of younger patients  [6] . The excess of severe first 
episodes in older patients accounted for an increased 
mortality rate of 19% compared with 1.7% for the entire 
study population.
 Surgery 
 Early surgical intervention has been recommended 
for elderly patients with severe UC, because postopera-
tive complications such as toxic megacolon, free perfora-
tion, massive hemorrhage, and mortality are more com-
mon in the elderly when surgery is delayed and per-
formed when they are critically ill  [1, 2] . It is unclear 
whether the higher mortality rate in elderly patients with 
UC, reaching 19% in some reports, is due to the disease 
process itself or the adverse effects of concomitant ill-
nesses  [1] . Postponing surgery on the basis of advanced 
age alone may increase mortality, whereas prompt surgi-
cal intervention has been associated with dramatic re-
ductions in mortality in elderly patients with severe coli-
tis  [41] . Nevertheless, surgery is still the definitive proce-
dure for the treatment of UC in adult and older patients, 
and its timing is of paramount importance. Morbidity of 
severe UC results from prolonged ineffective medical 
treatment and therefore a delay in surgical treatment 
should be avoided. The surgical procedure most com-
monly performed in adult and older patients is a subtotal 
abdominal colectomy and ileostomy, followed about 3 
months later (when the patient is off steroids with an im-
proved nutritional state) by completion proctectomy
and the formation of an ileal-pouch anal anastomosis 
(IPAA).
 Conclusion 
 Severe UC occurring in the elderly is an important is-
sue in the field of gastroenterology, considering that the 
proportion of elderly persons is increasing in our society. 
Sometimes, however, stoicism of the elderly patient is a 
formidable obstacle to early diagnosis. Severe UC must be 
considered a medical emergency especially in the elderly 
patient, even if the mortality rate for this disease is de-
creasing. Several factors might have contributed to the 
reduction in mortality that has been observed over the 
past 30 years, such as the widespread use of the Oxford 
(corticosteroid) regimen, which has now been integrated 
with the administration of cyclosporine and infliximab, 
the early detection of complications, the careful timing 
of surgery and the improved anesthesiological and surgi-
cal techniques. Key issues remain as to what should be 
first- and second-line therapies in different age groups, 
when surgery should be undertaken, and the risk of 
switching between immunosuppressants in these criti-
cally ill patients. As about 30% of severe UC cases con-
tinue to need colectomy, the timing of surgery and the 
collaboration between gastroenterologist and surgeon re-
main the most important goals in the management 
especially in older patients. More studies in different age 
groups in patients with severe UC are desperately needed 
and the management needs to be defined according to 
those studies.
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